Table 1.

Patient characteristics

	Arm A	Arm B	Arm C	Arm D	All Arms
	(N=7)	(N=7)	(N=12)	(N=25)	(N=51)
Age, median (range)	55 (30–69)	52 (37–69)	58 (45–83)	55 (28–78)	55 (28–83)
ECOG PS
0, n	4	6	3	14	27
1, n	3	1	9	11	24
Receptor Status
ER+, n	7	7	12	25	51
PR+, n	4	4	4	19	31
HER2+, n	0	0	0	0	0
Histology
Invasive ductal, n	5	7	8	21	41
Invasive lobular, n	2	0	2	4	8
Carcinoma NOS, n	0	0	2	0	2
Neoadjuvant or adjuvant chemotherapy, n	5 (71%)	5 (71%)	7 (58%)	13 (52%)	30 (59%)
Adjuvant endocrine therapy, n	5 (71%)	5 (71%)	10 (83%)	17 (68%)	37 (73%)
De novo metastatic, n	2 (29%)	2 (29%)	2 (17%)	8 (32%)	14 (27%)
Total number of therapies in metastatic setting, median (range)	3 (0–12)	5 (1–10)	4 (1–8)	4 (0–10)	4 (0–12)
Endocrine therapies, median (range)	2 (0–4)	2 (2–5)	2 (1–3)	2 (0–6)	2 (0–6)
Chemotherapies, median (range)	2 (0–9)	3 (0–8)	1 (0–5)	1 (0–5)	1 (0–9)
Endocrine Resistance, n	6 (86%)	7 (100 %)	11 (92%)	23 (92%)	27 (53%)
Sites of metastasis
Visceral disease, n	4	5	9	17	35
Bone only disease, n	3	2	3	8	16